EUCTR2012-002407-18-GB进行中（未招募）1 期
DPP4 inhibitors in Type 1 Diabetes - DPP4 inhibitors in Type 1 Diabetes Mellitus
niversity of Dundee and NHS Tayside0 个研究点目标入组 12 人开始时间: 2012年7月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •?Type 1 diabetes with greater than 5 years disease duration
- •?HbA1C<10%
- •?Age 18 and over.
- •?Current use of intensive insulin therapy (injections or pump)
- •?BMI 19-35
- •?Ability to give written informed consent to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •?Previous history of pancreatic disease/cancer
- •?Significant renal disease eGFR <50
- •?Personal/family history of Medullary thyroid cancer
- •?Personal/family history of MEN Type 2
- •?Moderate/Severe hepatic impairment (Child Pugh B,C)
- •?Pregnancy/Breast feeding
- •?History of epilepsy/hypoglycaemia induced seizure
- •?Those on any other hypoglycaemic drug apart from insulin for their diabetes.
- •?Currently on CYP3A4 inducers like carbamazepine, dexamethasone, phenobarbital, phenytoin and rifampicin
- •?Currently on CYP3A4 inhibitors like ketoconazole, diltiazem
研究者
相似试验
招募中
不适用
Efficacy and safety of DPP-4 inhibitors in diabetic patients undergoing hemodialysisJPRN-UMIN000018445Keiai Hospital60
已完成
不适用
Effect of DPP-4 inhibitor on insulin therapy for patients with type 2 diabetesType 2 diabetesJPRN-UMIN000006470Jikei University School of Medicine Kashiwa Hospital20
已完成
2 期
The effect of sitaglibtin (DPP4 inhibitor) administration in type 2 diabetes patients under insulin therapy regarding the weight, Lipid profile changes and blood glucose controlIRCT20191231045959N2Tabriz University of Medical Sciences60
已完成
不适用
In combination therapy with insulin and DPP-4 inhibitor sitagliptin Study of efficacy and safetyJPRN-UMIN000009908Diabetes Center,Tokyo Women's Medical University50
进行中（未招募）
不适用
ANTIDIABETIC EFFECTS OF ADDING A DPP-4 INHIBITOR (SITAGLIPTIN) TO PRE-EXISTING TREATMENT WITH AN INCRETIN MIMETIC (LIRAGLUTIDE) IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH METFORMITYPE 2 DIABETESMedDRA version: 16.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-001764-35-DEDiabeteszentrum Bad Lauterberg